“The data found EXPAREL use associated with improved clinical outcomes and a favorable cost savings per patient compared to the standard of care,” said a release.
EXPAREL was associated with a shorter length of hospital stay, greater mobility after surgery and a savings of $366 per patient on direct hospital costs.
“While our results were specific to a single institution and surgery type, we believe our methodology could serve as a model for minimizing the biases which often confound drug utilization evaluation studies, and help other institutions accurately assess the utility of EXPAREL,” said Carmen S. Kirkness, PT, PhD, who co-led the study.
More articles on orthopedics:
Orthopedic surgeon to know: Dr. David Jacofksy of The CORE Institute
ACL surgery: 5 things to know about health-related quality of life
Coordinated Health acquires Orthopedics Associates of the Greater Lehigh Valley
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.